Aclaris Therapeutics, Inc.

Related records

Trials (36)

• A Phase2 of A-101 Topical Solution in Subjects With Common Warts
• A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
• A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
• A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
• A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
• A Study of A-101 Solution in Subjects With Common Warts.
• A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
• A Study of A-101 Topical Solution for the Treatment of Common Warts
• A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
• A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
• A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
• A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
• An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
• An Open-Label Safety Study of A-101 Solution
• ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
• ATI-2231 in Advanced Solid Tumor Malignancies
• ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
• ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
• ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
• ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)